The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to refuse the application for a variation to the marketing authorisation for Hetlioz (tasimelteon).

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to refuse the application for a variation to the marketing authorisation for Hetlioz (tasimelteon).

老虎证券2026/03/27 11:54

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The decision upheld the committee's previous position, meaning the application from the relevant pharmaceutical company—Vanda Pharmaceuticals—was not approved this time.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to refuse the application for a variation to the marketing authorisation for Hetlioz (tasimelteon).

You may also like

Crypto prices